Drugs / pSRS11.EFS.IL2RG.pre
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01129544 | Apr 2010 → Mar 2023 | severe combined immunodeficiency | David Williams | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01175239 | Apr 2011 → Dec 2018 | severe combined immunodeficiency | Great Ormond Street Hospital for Children NHS Foundation Trust | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pSRS11.EFS.IL2RG.pre | “A SIN vector expressing the IL-2RG gene, pSRS11.EFS.IL2RG.pre” NCT01129544 ↗ |
| Known as | SIN-γc | “expressing γc (SIN-γc)” PMID 25295500 ↗ Oct 2014 |
| Action | Restore | “The idea behind gene transfer is to replace the broken gene by putting a piece of genetic material (DNA) that has the normal gene into the child's cells.” NCT01129544 ↗ |
| Modality | Cell therapy | “All patients received bone marrow-derived CD34+ cells transduced with the SIN-γc vector, without preparative conditioning.” PMID 25295500 ↗ Oct 2014 |
| Target | IL2RG | “A SIN vector expressing the IL-2RG gene” NCT01129544 ↗ |